NGS Controls & Reference Materials
Infectious Disease
SHOP PRODUCTSLGC Clinical Diagnostics - SeraCare's Seraseq infectious disease products support the promise of genomics in clinical diagnostics, treatment and drug resistance monitoring and disease surveillance. These patient-like reference materials enable the development, validation, and implementation of next-generation sequencing (NGS) assays for cancer diagnosis, treatment montoring, and patient stratification.
Features and benefits
- Reference materials accurately mimic real patient samples
- Reduce troubleshooting time
- Ensure lot-to-lot consistency
- Increase confidence in results
- Available in multiple formats (spike-in DNA/RNA, cultured organisms and recombinant virus)
- Manufactured in GMP-compliant and ISO 13485-certified facilities
Global Challenge - HIV Drug Resistance
HIV drug resistance, caused by mutations in the genetic structure of HIV, will affect the ability of a particular drug or combination of drugs to block the replication of the virus. All current anti-retroviral drugs, including newer classes, are at risk of becoming partially or fully inactive due to the emergence of resistant virus strains. To support assay developers and clinical labs to deliver the highest quality HIV drug resistance assays and patient outcomes, LGC Clinical Diagnostics - SeraCare offers Seraseq HIV Drug Resistance and Tropism Reference Materials in both cell-cultured and synthetic custom solutions that are:
- Applicable to NGS, Sanger Sequencing, PCR and Point-of-Care testing
- Manufactured under cGMP compliance in ISO 13485 certified facilities
- Key applications: assay development and monitoring, daily QC and troubleshooting
Cell-Cultured Reference Materials – available in 12 strains, stored at -70°C or colder customizable concentrations.
Synthetic Reference Materials – customizable variants, sequences and mutation frequency, stored at -20°C or colder.
- Spike-in DNA/RNA
- Recombinant viral particles - non-infectious and full-process control. To learn more about our AccuPlex technology, click here.
To learn more about our custom products and capabilities, please contact us.
To contribute to WHO's 95-95-95 target, we also offer an end-to-end quality control solution to support assay developers and clinical labs in bringing reliable HIV diagnostic, drug resistance, and viral load tests and results to HIV patients.
AccuSet™ HIV Verification Starter Packs (to be launched)
Other reference materials for NGS and other Molecular applications:
RELATED INFORMATION
- HIV End-to-end Quality Measurement Tools
- ACCURUN and AccuPlex Catalog
- Panel Catalog
- Custom Capabilities
